Research and development daily, Johnson opsumit and tadalafil reached the primary end point in phase IV clinical practice
-
Last Update: 2019-10-22
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Weigh! Only in March, FDA approved the breakthrough treatment of cystic fibrosis; the disease risk of refractory breast cancer patients was reduced by 46% HER2 specific TKI to reach the phase 3 clinical end point; Fosun Pharmaceutical holding company received the GMP certificate; Johnson opsumit combined with tadalafil reached the phase IV clinical end point We focus on the latest development of pharmaceutical research and development, and provide timely and accurate information reference for R & D personnel Today, vertex pharmaceuticals announced that the US FDA has approved the company's innovative therapies, trikafta (elexacaftor / tezacaftor / ivacftor and ivacftor), to be launched to treat patients over 12 years old with cystic fibrosis (CF) Today, Seattle genetics announced that its her specific oral small molecule tyrosine kinase inhibitor, tcatinib, reached the primary and secondary end points of the critical phase 3 trial her2climb in the treatment of locally advanced or metastatic HER2 positive breast cancer patients Seattle genetics plans to submit a new drug application (NDA) to the U.S FDA in the first quarter of 2020 Acotalon, a Johnson & Johnson company, recently released data from optima research On October 21, Shanghai Chaohui Pharmaceutical Co., Ltd., a subsidiary of Fosun Pharmaceutical, received the GMP certificate issued by Shanghai Drug Administration The production line certified in the GMP certificate is the N2 line of the second phase API workshop, and the certified products include aceglutamide The total investment for this certification is about 15 million yuan (Unaudited).
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.